Evaluation of combination therapy with tamsulosin and tolterodine for the treatment of chronic prostatitis/chronic pelvic pain syndrome
-
摘要:
目的 探讨坦索罗辛联合托特罗定治疗慢性前列腺炎/慢性盆腔疼痛综合征的临床疗效。 方法 将我院符合研究标准的64例确诊为慢性前列腺炎/慢性盆腔疼痛综合征的患者随机分为对照组和观察组。对照组给予口服坦索罗辛（0.2 mg，1次/d）联合抗菌药物治疗，观察组在此基础上联合使用托特罗定（4 mg，1次/d）治疗。两组患者于药物治疗前及连续用药12周后进行慢性前列腺炎症状评分、视觉模拟评分，比较最大尿流率、平均尿流率及前列腺液中的白细胞数目，评估治疗效果，并在治疗期间评估患者的用药依从性情况。 结果 经治疗后，观察组患者慢性前列腺炎症状总评分（16.34±4.31）、视觉模拟评分（4.22±1.70）、白细胞数目（7.16±3.35）、排尿症状评分（2.78±1.56）、QOL评分（5.44±2.23）以及用药依从性评分（0.84±0.85）均有下降。最大尿流率（19.47±4.69）、平均尿流率（11.91±3.85）显著升高，且各项指标均优于对照组（分别为24.16±4.95、6.34±1.62、14.78±4.64、5.78±2.09、8.41±2.67、1.22±0.67），差异具有统计学意义（P<0.05）。 结论 坦索罗辛联合托特罗定治疗慢性前列腺炎/慢性盆腔疼痛综合征能获得更好的疗效，值得临床重视。 -
关键词:
- 坦索罗辛 /
- 托特罗定 /
- 慢性前列腺炎/慢性盆腔疼痛综合征 /
- 临床观察
Abstract:Objeetive To evaluate the effect of combination therapy of toherodine and tamsulosin in improving symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods A total of 64 patients with CP/CPPS in our hospital were randomized into control group and observation group, with 32 cases in each group. The control group was treated with tamsulosin (2 mg, qd), while the observation group was treated with tamsulosin (2 mg, qd) combined with tolterodine (4 mg, qd). Chronic prostatitis symptom index (CPSI), Visual analogue scale (VAS), maximum flow rate (MFR), average flow rate (AFR), white blood cell (WBC) of ESP were compared before treatment and after 12 weeks. The patients’ compliance in two groups’ patients was investigated as well. Results After treatment, The observation group have decreased in NIH-CPSI (16.34±4.31), VAS (4.22±1.70), WBC (7.16±3.35), urinary symptom score (2.78±1.56), QOL (5.44±2.23) and Morisky (0.84±0.85). MFR (19.47±4.69)、AFR (11.91±3.85) were significantly increased, and the indexes were better than control group (24.16±4.95、6.34±1.62、14.78±4.64、5.78±2.09、8.41±2.67、1.22±0.67).The difference was statistically significant (P<0.05). Conclusion Combination therapy of toherodine and tamsulosin is better than tamsulosin hydrochloride alone in treatment of CP/CPPS. -
Key words:
- tamsulosin /
- tolterodine /
- chronic prostatitis/chronic pelvic pain syndrome /
- evaluation
-
表 1 两组患者治疗前后的疼痛症状、排尿症状及NIH-CPSI评分的比较
组别 排尿症状评分 QOL NIH-CPSI 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 观察组 6.81±2.10 2.78±1.56a 8.68±1.96 5.44±2.23a 32.03±4.50 16.34±4.31a 对照组 6.72±1.85 5.78±2.09 9.28±1.76 8.41±2.67 32.41±3.74 24.16±4.95a t 0.195 -6.258 1.203 4.463 0.351 -7.416 P 0.846 0.000 0.238 0.000 0.728 0.000 aP<0.01vs 治疗前. 
下载: 导出CSV
表 2 两组患者治疗前后最大尿流率及平均尿流率的比较
组别 最大尿流率 平均尿流率 治疗前 治疗后 治疗前 治疗后 观察组 14.03±4.30 19.47±4.69a 8.47±3.61 11.91±3.85a 对照组 13.81±4.01 16.62±4.88a 8.34±3.33 10.56±3.65b t 0.200 2.549 0.113 1.449 P 0.843 0.016 0.911 0.157 aP<0.01vs 治疗前；bP<0.05vs 治疗前.
下载: 导出CSV
表 3 两组患者治疗前后的视觉模拟评分、WBC及用药依从性评分评分比较
组别 视觉模拟评分 WBC 用药依从性评分 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 观察组 8.28±1.89 4.22±1.70a 20.59±5.27 7.16±3.35a 1.78±1.04 0.84±0.85a 对照组 8.13±1.74 6.34±1.62a 20.13±5.87 14.78±4.64a 1.69±1.23 1.22±0.67 t 0.402 -4.836 0.325 7.802 0.294 2.104 P 0.691 0.000 0.747 0.000 0.771 0.044 aP<0.01vs 治疗前.
下载: 导出CSV
-
[1] Rees J, Abrahams M, Doble A, et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline[J]. BJU Int, 2015, 116(4): 509-25. doi: 10.1111/bju.13101 [2] 吴阶平. 吴阶平泌尿外科学[M]. 济南: 山东科学技术出版社, 2005. [3] 那彦群, 叶章群, 孙颖浩, 等. 中国泌尿外科疾病诊断治疗指南: 2014版[M]. 北京: 人民卫生出版社, 2013: 449-56. [4] 李健生. 坦索罗辛联合托特罗定改善老年男性帕金森病患者下尿路症状效果观察[J]. 山东医药, 2016, 12(4): 75-6. http://www.cnki.com.cn/Article/CJFDTOTAL-SDYY201604035.htm [5] 戴继灿. 介绍美国国立卫生研究院慢性前列腺炎症状积分指数(NIH-CPSI) [J]. 中国男科学杂志, 2000, 14(1): 62-4. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZJKX200712006037.htm [6] Luzzi GA. Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management[J]. J Europ Acad Dermat Vener, 2002, 16(3): 253-6. doi: 10.1046/j.1468-3083.2002.00481.x [7] 邓春华, 梁 宏, 梅 骅. 前列腺内尿液返流在慢性前列腺炎发病中的作用[J]. 中华泌尿外科杂志, 1998, 19(6): 288-9. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHMN806.015.htm [8] Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis) [J]. BJU Int, 2004, 93(7): 991-5. doi: 10.1111/j.1464-410X.2003.04766.x [9] Cheah PY, Liong ML, Yuen KH, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial[J]. J Urol, 2003, 169(2): 592-6. doi: 10.1016/S0022-5347(05)63960-2 [10] Nickel JC, Downey J, Johnston B, et al. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial[J]. J Urol, 2001, 165(5): 1539-44. doi: 10.1016/S0022-5347(05)66344-6 [11] Ishigooka M, Nakada T, Hashimoto T, et al. Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate[J]. Urology, 2002, 59(1): 139-44. doi: 10.1016/S0090-4295(01)01470-4 [12] 秦国东, 肖明朝, 周远大, 等. 坦索罗辛对大鼠细菌性前列腺炎组织中左氧氟沙星药动学的影响[J]. 中国抗生素杂志, 2013, 38(1): 78-82. http://www.cnki.com.cn/Article/CJFDTOTAL-ZKSS201301016.htm [13] 姚 斌, 范晓萍, 邵四海. 坦索罗辛, 左氧氟沙星单用与联用治疗Ⅲ型前列腺炎的临床观察[J]. 中国药房, 2015, 35(12): 1624-6. doi: 10.6039/j.issn.1001-0408.2015.12.15 [14] Chen Y, Wu X, Liu J, et al. Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial[J]. World J Urol, 2011, 29(3): 381-5. doi: 10.1007/s00345-010-0537-3 [15] 许晓艳, 刘利维, 韩瑞发. 前列舒通联合α受体阻滞剂治疗慢性前列腺炎的疗效观察[J]. 中国中西医结合外科杂志, 2014, 9(1): 55-7. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGZX201401017.htm [16] 马 强, 陈 卓, 贾国金, 等. 联合药物治疗慢性前列腺炎的疗效分析: 附253例报告[J]. 中国临床医学, 2015, 18(5): 631-2. http://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201505015.htm [17] 桂金勇, 童宏华, 杨巧英, 等. 索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床效果分析[J]. 赣南医学院学报, 2015, 17(1): 116-7. http://www.cnki.com.cn/Article/CJFDTOTAL-DDYI201602081.htm [18] 孙祥宙, 刘贵华, 高 勇, 等. 盐酸特拉唑嗪联合酒石酸托特罗定治疗Ⅲ型前列腺炎40例[J]. 广东医学, 2008, 29(10): 1611-3. doi: 10.3969/j.issn.1001-9448.2008.10.007 [19] Ruggieri MR, Braverman AS, Pontari MA. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction[J]. J Urol, 2005, 174(5): 1743-8. doi: 10.1097/01.ju.0000176460.62847.23 -
点击查看大图
表(3)
计量
- 文章访问数: 1008
- HTML全文浏览量: 281
- PDF下载量: 9
- 被引次数: 0
